MRTX1719
CA240-0009
Phase 2 small_molecule active
Quick answer
MRTX1719 for Advanced or Metastatic Non-small Cell Lung Cancer is a Phase 2 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Advanced or Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active